Peet M
Department of Psychiatry, Northern General Hospital, Sheffield.
Br J Psychiatry. 1994 Apr;164(4):549-50. doi: 10.1192/bjp.164.4.549.
The rate of treatment-emergent switch into mania has been calculated from all available clinical trial data on the selective serotonin re-uptake inhibitors (SSRIs) fluoxetine, fluvoxamine, paroxetine, and sertraline, relative to comparative groups treated with tricyclic antidepressants (TCAs) or placebo. In predominantly unipolar depressives, the rate of manic switch is less than 1% and differences between drugs and placebo are statistically but not clinically significant. In bipolar depressives, manic switch occurs substantially more often with TCAs (11.2%) than with SSRIs (3.7%) or placebo (4.2%).
已根据选择性5-羟色胺再摄取抑制剂(SSRI)氟西汀、氟伏沙明、帕罗西汀和舍曲林的所有现有临床试验数据,相对于接受三环类抗抑郁药(TCA)或安慰剂治疗的对照组,计算出治疗中出现转躁狂的发生率。在以单相抑郁为主的患者中,转躁狂发生率低于1%,药物与安慰剂之间的差异在统计学上有意义,但在临床上无显著差异。在双相抑郁患者中,TCA治疗时转躁狂的发生率(11.2%)显著高于SSRI(3.7%)或安慰剂(4.2%)。